237 related articles for article (PubMed ID: 27930339)
21. Cellular mechanisms of growth inhibition of human endometrial cancer cell line by an antagonist of growth hormone-releasing hormone.
Zhao L; Yano T; Osuga Y; Nakagawa S; Oishi H; Wada-Hiraike O; Tang X; Yano N; Kugu K; Schally AV; Taketani Y
Int J Oncol; 2008 Mar; 32(3):593-601. PubMed ID: 18292936
[TBL] [Abstract][Full Text] [Related]
22. Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities.
Zarandi M; Varga JL; Schally AV; Horvath JE; Toller GL; Kovacs M; Letsch M; Groot K; Armatis P; Halmos G
Proc Natl Acad Sci U S A; 2006 Mar; 103(12):4610-5. PubMed ID: 16537407
[TBL] [Abstract][Full Text] [Related]
23. The effect of a novel antagonist of growth hormone releasing hormone on cell proliferation and on the key cell signaling pathways in nine different breast cancer cell lines.
Pozsgai E; Schally AV; Hocsak E; Zarandi M; Rick F; Bellyei S
Int J Oncol; 2011 Oct; 39(4):1025-32. PubMed ID: 21701777
[TBL] [Abstract][Full Text] [Related]
24. Agonist of growth hormone-releasing hormone enhances retinal ganglion cell protection induced by macrophages after optic nerve injury.
Cen LP; Ng TK; Liang JJ; Xu C; Zhuang X; Liu YF; Chen SL; Xu Y; Yang Q; Yuan XL; Qin YJ; Chan SO; Chen H; Zhang M; Schally AV; Pang CP
Proc Natl Acad Sci U S A; 2021 Jul; 118(28):. PubMed ID: 34244423
[TBL] [Abstract][Full Text] [Related]
25. Downregulation of p21-activated kinase-1 inhibits the growth of gastric cancer cells involving cyclin B1.
Liu F; Li X; Wang C; Cai X; Du Z; Xu H; Li F
Int J Cancer; 2009 Dec; 125(11):2511-9. PubMed ID: 19610058
[TBL] [Abstract][Full Text] [Related]
26. Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins.
Stangelberger A; Schally AV; Rick FG; Varga JL; Baker B; Zarandi M; Halmos G
Prostate; 2012 Apr; 72(5):555-65. PubMed ID: 21796649
[TBL] [Abstract][Full Text] [Related]
27. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
[TBL] [Abstract][Full Text] [Related]
28. Antinflammatory, antioxidant, and behavioral effects induced by administration of growth hormone-releasing hormone analogs in mice.
Recinella L; Chiavaroli A; Orlando G; Ferrante C; Marconi GD; Gesmundo I; Granata R; Cai R; Sha W; Schally AV; Brunetti L; Leone S
Sci Rep; 2020 Jan; 10(1):732. PubMed ID: 31959947
[TBL] [Abstract][Full Text] [Related]
29. Antagonists of growth hormone-releasing hormone inhibit the proliferation of human benign prostatic hyperplasia cells.
Siejka A; Schally AV; Block NL; Barabutis N
Prostate; 2010 Jul; 70(10):1087-93. PubMed ID: 20232355
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of estrogen receptor positive and negative breast cancer cell lines with a growth hormone-releasing hormone antagonist.
Seitz S; Hohla F; Schally AV; Moder A; Engel JB; Horn F; Varga J; Zarandi M; Ortmann O; Köster F; Buchholz S
Oncol Rep; 2008 Nov; 20(5):1289-94. PubMed ID: 18949435
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic Upregulation of Metallothionein 2A by Diallyl Trisulfide Enhances Chemosensitivity of Human Gastric Cancer Cells to Docetaxel Through Attenuating NF-κB Activation.
Pan Y; Lin S; Xing R; Zhu M; Lin B; Cui J; Li W; Gao J; Shen L; Zhao Y; Guo M; Wang JM; Huang J; Lu Y
Antioxid Redox Signal; 2016 May; 24(15):839-54. PubMed ID: 26801633
[TBL] [Abstract][Full Text] [Related]
32. Growth Hormone-Releasing Hormone in Lung Physiology and Pulmonary Disease.
Zhang C; Cui T; Cai R; Wangpaichitr M; Mirsaeidi M; Schally AV; Jackson RM
Cells; 2020 Oct; 9(10):. PubMed ID: 33096674
[TBL] [Abstract][Full Text] [Related]
33. Growth hormone-releasing hormone antagonists abolish the transactivation of human epidermal growth factor receptors in advanced prostate cancer models.
Muñoz-Moreno L; Arenas MI; Carmena MJ; Schally AV; Prieto JC; Bajo AM
Invest New Drugs; 2014 Oct; 32(5):871-82. PubMed ID: 25000999
[TBL] [Abstract][Full Text] [Related]
34. The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas.
Busto R; Schally AV; Varga JL; Garcia-Fernandez MO; Groot K; Armatis P; Szepeshazi K
Proc Natl Acad Sci U S A; 2002 Sep; 99(18):11866-71. PubMed ID: 12186980
[TBL] [Abstract][Full Text] [Related]
35. Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers.
Klukovits A; Schally AV; Szalontay L; Vidaurre I; Papadia A; Zarandi M; Varga JL; Block NL; Halmos G
Cancer; 2012 Feb; 118(3):670-80. PubMed ID: 21751186
[TBL] [Abstract][Full Text] [Related]
36. Expression of Receptors for Pituitary-Type Growth Hormone-Releasing Hormone (pGHRH-R) in Human Papillary Thyroid Cancer Cells: Effects of GHRH Antagonists on Matrix Metalloproteinase-2.
Catanuto P; Tashiro J; Rick FG; Sanchez P; Solorzano CC; Glassberg MK; Block NL; Lew JI; Elliot SJ; Schally AV
Horm Cancer; 2015 Jun; 6(2-3):100-6. PubMed ID: 25752763
[TBL] [Abstract][Full Text] [Related]
37. Activation of Janus kinase/signal transducer and activator of transcription 3 pathway by growth hormone-releasing hormone.
Siejka A; Schally AV; Barabutis N
Cell Mol Life Sci; 2010 Mar; 67(6):959-64. PubMed ID: 20012909
[TBL] [Abstract][Full Text] [Related]
38. Regulation of Vascular Calcification by Growth Hormone-Releasing Hormone and Its Agonists.
Shen J; Zhang N; Lin YN; Xiang P; Liu XB; Shan PF; Hu XY; Zhu W; Tang YL; Webster KA; Cai R; Schally AV; Wang J; Yu H
Circ Res; 2018 May; 122(10):1395-1408. PubMed ID: 29618597
[TBL] [Abstract][Full Text] [Related]
39. Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice.
Chatzistamou I; Schally AV; Varga JL; Groot K; Armatis P; Busto R; Halmos G
J Clin Endocrinol Metab; 2001 May; 86(5):2144-52. PubMed ID: 11344219
[TBL] [Abstract][Full Text] [Related]
40. Troxerutin (TXN) potentiated 5-Fluorouracil (5-Fu) treatment of human gastric cancer through suppressing STAT3/NF-κB and Bcl-2 signaling pathways.
Xu GY; Tang XJ
Biomed Pharmacother; 2017 Aug; 92():95-107. PubMed ID: 28531805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
